Location History:
- Charleston, SC (US) (1979 - 1980)
- Rockville, MD (US) (1986 - 1989)
- Orinda, CA (US) (1997)
- Richardson, TX (US) (1999)
- Oakland, CA (US) (2016 - 2019)
- Woodbury, NY (US) (2019)
- Boca Raton, FL (US) (2024)
Company Filing History:
5 out of 1,217 
3 out of 3 
1 out of 1 
Years Active: 1979-2024
Title: Innovator in Antileukemic Research: The Contributions of Paul Schwartz
Introduction: Paul Schwartz, an accomplished inventor based in Charleston, South Carolina, has made significant strides in the field of medical research, particularly in the development of antileukemic compounds. With a total of five patents to his name, Schwartz's innovative work has not only advanced scientific understanding but also holds promise for future cancer treatments.
Latest Patents: Among his notable patents, Schwartz's latest invention involves the use of 4-carboxy-phthalato(1,2-diaminocyclohexane)-platinum(II) and its alkali metal salts, which have demonstrated antileukemic activities against murine leukemia L1210. This compound is effective in dosages ranging from 5 to 60 mg/kg of body weight, showing potentiation when combined with cyclophosphamide (CY) and potentially enhanced by the addition of 5-fluorouracil (5-FU) or hydroxyurea (HU). Notably, previous platinum chelate compounds faced limitations due to renal impairment; however, the free carboxyl group present in Schwartz's compound shows promise for oral administration and better absorption. The preparation of this platinum compound involves a reaction between dichloro(1,2-diaminocyclohexane)platinum(II) and silver nitrate, followed by the addition of benzene tricarboxylic acid.
Career Highlights: Schwartz's inventive spirit and rigorous research have led to advancements that challenge existing treatment limitations. His compound, denoted as Pt-307, stands out for demonstrating superior results in renal toxicity testing compared to its parent compound and proves effective against strains of murine leukemia that have developed resistance to previous treatments.
Collaborations: Throughout his career, Paul Schwartz has collaborated with notable professionals in the field, including Glen R. Gale, enhancing the impact of his innovative endeavors. Their collective efforts have culminated in significant advancements in cancer research, particularly in the formulation of effective treatment regimens.
Conclusion: Paul Schwartz's contributions to the field of medical research, particularly through his patented innovations in antileukemic treatments, underscore his role as a pivotal figure in the fight against cancer. As a member of The United States of America as Represented by the Department of Health, he continues to pave the way for future advancements that may transform cancer therapy and improve patient outcomes.